USC NORRIS CANCER HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $93.4M
- Transactions
- 3,047
- Companies
- 40
- Average per transaction
- $30,654
Who reported the payments
| Eisai Inc. | $32,965,688 |
| Eli Lilly | $23,691,709 |
| Merck | $6,759,310 |
| Pfizer | $6,386,599 |
| Janssen Research & Development, LLC | $3,774,440 |
| AbbVie | $2,696,038 |
| Bayer | $2,168,557 |
| Novartis | $1,020,380 |
| Gilead | $895,473 |
| E.r. Squibb & Sons, L.L.C. | $867,394 |
| Otsuka Pharmaceutical Co., Ltd. | $745,865 |
| Intuitive Surgical | $686,959 |
| Boston Scientific | $615,057 |
| Takeda Pharmaceuticals U.S.A., Inc. | $592,624 |
| Abbott | $481,984 |
| Amgen | $412,009 |
| Boehringer Ingelheim | $377,540 |
| Intercept Pharmaceuticals, Inc. | $373,504 |
| LEO Pharma AS | $345,782 |
| Neurocrine Biosciences, Inc. | $342,600 |
| Adaptive Biotechnologies Corporation | $329,400 |
| Kyowa Kirin Pharmaceutical Development, Inc | $311,361 |
| Incyte Corporation | $307,981 |
| Siemens Medical Solutions USA, Inc. | $304,098 |
| AstraZeneca | $291,164 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $275,354 |
| Regeneron | $266,460 |
| Angiodynamics, Inc. | $211,667 |
| Travere Therapeutics, Inc. | $200,000 |
| Servier Bioinnovation | $198,926 |
| Seagen Inc. | $193,092 |
| Daiichi Sankyo Inc. | $174,272 |
| Biotest AG | $172,816 |
| Paratek Pharmaceuticals, Inc. | $158,259 |
| Biogen | $152,871 |
| United Therapeutics Corporation | $147,165 |
| Edwards Lifesciences | $136,412 |
| Alkermes, Inc. | $135,000 |
| Intuitive Surgical Operations, Inc. | $134,375 |
| Cathworks, Inc. | $120,054 |